Quick Answer
NEUROCRINE BIOSCIENCES INC reported Operating Income Loss of $619.10 million for the year ending 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +8.5% in Operating Income Loss from 2024 to 2025.
- This data is from NEUROCRINE BIOSCIENCES INC's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$5.89 million | Q3 2010: $2.47 million | Q1 2011: $1.94 million | Q2 2011: $1.10 million | Q3 2011: $30.44 million | Q1 2012: -$1.79 million | Q2 2012: -$1.38 million | Q3 2012: -$3.96 million | Q1 2013: -$12.98 million | Q2 2013: -$13.17 million | Q3 2013: -$12.01 million | Q1 2014: -$12.73 million | Q2 2014: -$14.36 million | Q3 2014: -$16.86 million | Q1 2015: -$2.29 million | Q2 2015: -$25.32 million | Q3 2015: -$35.84 million | Q1 2016: -$20.86 million | Q2 2016: -$41.83 million | Q3 2016: -$38.44 million | Q1 2017: -$79.93 million | Q2 2017: -$57.27 million | Q3 2017: -$6.00 million | Q1 2018: -$37.45 million | Q2 2018: -$1.85 million | Q3 2018: $54.32 million | Q1 2019: -$101.00 million | Q2 2019: $34.40 million | Q3 2019: $90.10 million | Q1 2020: $58.90 million | Q2 2020: $76.60 million | Q3 2020: -$44.30 million | Q1 2021: $31.50 million | Q2 2021: $62.80 million | Q3 2021: $44.50 million | Q1 2022: $3.10 million | Q2 2022: $54.70 million | Q3 2022: $87.80 million | Q1 2023: -$114.20 million | Q2 2023: $73.60 million | Q3 2023: $141.20 million | Q1 2024: $99.30 million | Q2 2024: $145.40 million | Q3 2024: $183.80 million | Q1 2025: $23.60 million | Q2 2025: $145.60 million | Q3 2025: $239.00 million.
- Over the full 17 years of available data (2009 to 2025), NEUROCRINE BIOSCIENCES INC's Operating Income Loss has grown by 1,253.5%.
- Historical annual values: Fiscal year 2025: $619.10 million | Fiscal year 2024: $570.50 million | Fiscal year 2023: $250.90 million | Fiscal year 2022: $249.00 million | Fiscal year 2021: $102.50 million | Fiscal year 2020: $163.00 million | Fiscal year 2019: $72.30 million | Fiscal year 2018: $36.80 million | Fiscal year 2017: -$131.36 million | Fiscal year 2016: -$147.37 million | Fiscal year 2015: -$94.20 million | Fiscal year 2014: -$64.41 million | Fiscal year 2013: -$49.68 million | Fiscal year 2012: $1.45 million | Fiscal year 2011: $33.92 million | Fiscal year 2010: -$13.72 million | Fiscal year 2009: -$53.67 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: